Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Navitoclax in KRAS or NRAS Mutation-Positive Advanced Solid Tumors
NCT02079740Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib, navitoclax in solid tumor, sponsored by National Cancer Institute. Started Mar 2014; status: active, not recruiting.
02
Drugs
trametinibnavitoclax
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02079740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079740.